A swallowtail butterfly in England is on the red list. Half of Britain’s ash trees are projected to die. Chytrid fungus has driven declines in more than 500 amphibian species and pushed 90 to outright extinction. These are not hypotheticals. They are the present, and the present is accelerating.
I have watched the same argument arrive on my own forty acres in Adams County, Wisconsin: protect the woods, draw the boundary, hope the old conditions return. The notebook says they do not. The ice goes out earlier. The mosquitoes come sooner. The deer move on a different calendar. And the fences themselves have not held. The town on the south side of the county lost a church, lost the grocery, watched the bank consolidate out of existence. Conservation easements and protected lands did not cause any of that. But they could not stop it either, because a boundary cannot protect a membership that has been priced, taxed, and bought out of the place it was drawn around. Across Wisconsin the pattern repeats — frog populations vanish from streams that still show on the maps, heron rookeries go silent, warm-water species creep northward through watersheds that no treaty or easement can cool. Lake Petenwell gets an algal bloom every August now where it did not used to. The old toolkit has been deployed for fifty years in rural America and the curve is still bending the wrong way.
So when the United Kingdom’s Advanced Research and Invention Agency — Aria, the tax-funded “invention agency” conceived by Dominic Cummings to bankroll “crazy” ideas — dropped £30 million on Monday across fourteen research teams, the only sane reaction was: finally.
Finally, someone is treating biodiversity collapse like the engineering problem it has become.
The programme will spend £54 million through 2030, with a further £24 million reserved for projects that prove themselves during the first two years. The work runs from CRISPR-edited swallowtail butterflies at the University of Exeter to oak trees at the 180-year-old Rothamsted Research in Hertfordshire, where researchers are rewriting genomes so the trees can reproduce in months instead of decades.
At Cardiff University, mycologist Sarah Christofides is developing RNA injections that act like vaccines for ash trees facing a fungal death sentence. Cultivarium, working with Imperial College London and Queen Mary University of London, is engineering skin bacteria that could shield amphibians from chytrid fungus by producing antifungal proteins that bind and neutralize the pathogen.
Crispr for butterflies. RNA vaccination for trees. Engineered skin microbes for frogs and newts.
This is what high-reward science looks like. Not incremental. Not polite. Not content to watch a species disappear while another committee updates the red list.
The old toolkit has been fighting a twenty-first-century war with a twentieth-century doctrine. It protects what is there. It does not necessarily give what is there the means to survive what is coming.
That matters here, not only in Britain. Ash dieback is a fungal disease marching across Europe. There is no reason it will stop at the English Channel and spare the ash stands on my neighbor’s forty. If it takes half of Britain’s ash trees, the timber value lost runs into the hundreds of millions of pounds. If it reaches Adams County, the damage lands on a landowner who is already stretching a $48,000 shop income across a family and a mortgage, counting every tree on the back forty as part of a balance sheet that does not have much margin in it. The bumblebee that Aria’s programme aims to protect is not an abstraction. It is the pollinator on the pumpkin patch, on the squash row, on the neighbor’s berry patch down the road. A working pollinator population is not a nice-to-have. It is the infrastructure of a rural household’s food supply and small-acreage income.
The English oak needs decades to reproduce. The swallowtail cannot evolve on command while insecticides coat the farmland around its remaining wetlands. The ash tree cannot simply decide to develop resistance to a fungus that has marched across a continent. The climate is moving faster than wild populations can adapt.
That is the gap Aria is funding.
The agency came from Dominic Cummings’s ambition to “restore Britain’s place as a scientific superpower.” That origin deserves scrutiny. So does every public institution that spends public money on private contractors, venture capital, or foreign technology firms. But the core question is whether the work is worth funding, not whether the person who first proposed it passes every test we would set for a co-op board member.
Polite funding bodies do not produce gene-edited butterflies. They do not produce skin vaccines for amphibians. They do not move a tree’s reproductive clock from decades to months.
That is why the objections matter. They just do not settle the question.
At last October’s International Union for Conservation of Nature world conservation congress, more than 90 NGOs objected that synthetic biology could “irreversibly alter natural systems with unpredictable effects.” A proposed ban was narrowly rejected after an open letter signed by 250 scientists argued that these tools could also help a small island remove invasive mice threatening more than a hundred bird and reptile species.
The IUCN adopted its first global synthetic-biology policy instead.
Stringent criteria, not a halt.
That is the right answer. The right answer is yes, with rules. The wrong answer is no, with appeals to a nature that is no longer there to defend itself.
The programme has guardrails. No experimental solution will be released into the wild during the funding period, which runs to 2030. All grantees will work in secure laboratories. Field deployment, if it ever comes, will require approval from the Department for Environment, Food and Rural Affairs. Defra has long controlled the release of genetically modified organisms in Britain.
Marie-Claire Cordonier Segger of Cambridge chairs the programme’s ethics and social-responsibility advisory committee. The framework draws directly on the IUCN policy. Cordonier Segger has described it as “the strongest possible code.”
This is not a rogue moonshot. It is a cautious, well-governed, deliberately slow-moving programme to give wild species some of the technological chance that human medicine has given us.
The medical analogy is not decorative. Yannick Wurm, the evolutionary genomics professor at Queen Mary University of London who directs the Accelerated Adaptation Programme, calls these interventions the mRNA vaccines of conservation. That is not science fiction. It is a way to describe the possibility that a targeted biological intervention might protect a population before the old biological timetable catches up.
The alternative is measured too.
Dead trees. Vanished butterflies. Silent ponds. Timber value that does not show up on the county assessor’s roll because the trees were alive when the assessment was made and dead before the tax bill arrived.
Chris Thomas of the University of York’s Leverhulme Centre for Anthropocene Biodiversity, who is not part of the Aria programme, warns that biotechnology may deliver only “modest” gains and that technical fixes could distract from the deeper work of stopping the human drivers of environmental collapse.
He is right about the modesty. He is right that the drivers must be stopped. He is wrong if modest gains are treated as an argument against making them.
A modest gain applied across hundreds of species and millions of acres is not a small thing. It is the difference between a living planet and a museum.
One modified species in one pond will change the relationships around it. Chytrid resistance will be uneven across amphibian populations. A tree vaccine will not repair every damaged watershed. None of that is a reason to pretend the choice is between untouched nature and reckless engineering.
The choice is between governed intervention and unmanaged extinction.
Aria has had its bruising moments. Its chair, Matt Clifford was forced to step down after taking a role with the artificial-intelligence company Anthropic, a move one senior member of Parliament called a “clear conflict of interest.” The agency has also drawn criticism over grants that directed British taxpayer money toward United States technology firms and venture capital.
Those are governance problems. Governance problems are fixable.
Climate-driven extinction is not.
A public institution that claims permission to alter living systems must be transparent about who is paid, who decides, who benefits, who bears the risk, and who can stop the work. It needs independent review, public records, strict containment, and a clear line between laboratory promise and field release. Aria is not entitled to trust. It has to earn it.
But caution is not the same as paralysis. The precautionary reflex becomes its own kind of recklessness when it protects our comfort while species pay the bill.
Yannick Wurm hopes that a handful of successes will be “world-changing.” That is the right aspiration. Conservation biology has spent half a century setting its ceiling at slowing the loss. It is time to set the ceiling at reversing it.
The most urgent challenge remains the one Wurm identifies: halt and reverse the human drivers of environmental change. Stop poisoning habitats. Stop dismantling wetlands. Stop treating land, water, and living things as disposable inputs. The laboratory is not a substitute for that work.
But it is also not an excuse to withhold tools from the species already standing in the fire.
The swallowtail, the ash, the oak, the bumblebee, the newt, and the frog do not have the luxury of waiting for human politics to become wise. They are going to need every tool twenty-first-century biology can put into the hands of people willing to use those tools under rules.
The planet does not need more apologies for laboratories.
It needs more laboratories.
And this week, Britain funded fourteen.